247wallst.com Open in urlscan Pro
2606:4700:10::6816:3b6  Public Scan

Form analysis
1 forms found in the DOM

GET https://247wallst.com

<form id="searchform" class="field has-addons" method="get" action="https://247wallst.com"> <input type="text" name="s" value="" placeholder="Search 24/7 Wallst." id="searchbox" class="input"> <input type="submit" value="Search"
    id="site_search_button" class="subscribe button"> </form>

Text Content

Skip to content
City Data Centers
Crime by State Cost of Living by State Population and Demographics by State
Crime by State
Alabama Alaska Arizona Arkansas California Colorado Connecticut
Delaware Florida Georgia Hawaii Idaho Illinois Indiana
Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts
Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada
New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio
Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee
Texas Utah Vermont Virginia Washington West Virginia Wisconsin
Wyoming
Cost of Living by State
Alabama Alaska Arizona Arkansas California Colorado Connecticut
Delaware Florida Georgia Hawaii Idaho Illinois Indiana
Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts
Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada
New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio
Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee
Texas Utah Vermont Virginia Washington West Virginia Wisconsin
Wyoming
Population and Demographics by State
Alabama Alaska Arizona Arkansas California Colorado Connecticut
Delaware Florida Georgia Hawaii Idaho Illinois Indiana
Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts
Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada
New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio
Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee
Texas Utah Vermont Virginia Washington West Virginia Wisconsin
Wyoming
Technology
Apps & Software Consumer Electronics Telecom & Wireless
Trending



HAS APPLE SOLD 20 MILLION IPHONE 15S?

Investors face a difficult problem. How do they handicap iPhone...
Investing
Analyst Upgrades Bankruptcy Buffett Corporate Governance Corporate Performance
Dividends and Buybacks Earnings ETFs and Mutual Funds International Markets IPOs
and Secondaries
Mergers and Acquisitions Personal Finance Rumors Value Investing
Trending



5 SIZZLING CATHIE WOOD ARK INVESTMENT STOCKS TRADE...

These are five stocks for aggressive investors looking to get...
Economy
Government Regulation Housing Jobs
Trending



THE STATE WITH THE HIGHEST DIVORCE RATE

Almost 700,000 people get divorced each year, causing havoc with...
Special Report
Brands and Products Cities Countries States
Trending



THESE AMERICANS OWN THE MOST GUNS: EVERY STATE RANKED

Gun ownership is a constitutional right in the United States,...

Investing


THE 3 TOP PHARMA STOCKS TO BUY IN SEPTEMBER 2024

Triff / Shutterstock.com
Chris MacDonald
Published: September 23, 2024 8:52 am


Pharma stocks have been on quite a nice run over the past year. A number of new
catalysts have revitalized this sector, which I’m going to dive into with a few
of these picks. Whether we’re talking about innovative new drugs aimed at weight
loss and other cancers or ailments, or simply greater operating efficiency and
returns on capital, there are reasons why many investors continue to scour this
sector for growth.

It hasn’t always been like this. In fact, many top big pharma names have
struggled to provide meaningful growth over the past decade. Outside of certain
Covid vaccine catalysts, and some mergers and acquisitions activity in the
space, it’s been relatively slow going for longer-term investors. However, the
tide does appear to be changing, and these three stocks do look well-positioned
to continue to capitalize on certain growth catalysts in this sector.



Without further ado, here are three top pharma stocks I think represent buying
opportunities in September.


KEY POINTS ABOUT THIS ARTICLE:

 * Growth catalysts are beginning to emerge for a number of top pharma players,
   a welcome reality for many investors in this sector.
 * Here are three of the top pharma plays for September 2024 I think are worth
   considering here.
 * If you’re looking for some stocks with huge potential, make sure to grab a
   free copy of our brand-new “The Next NVIDIA” report. It features a software
   stock we’re confident has 10X potential.


ELI LILLY (LLY)

jetcityimage / iStock Editorial via Getty Images
An Eli Lilly sign outside of the company’s head office

Eli Lilly (NYSE:LLY) has certainly been among the big winners over the past five
years in the pharma space. The company’s stock price has surged 770% over this
time frame, reaching all-time highs in 2024 due to the success of its diabetes
and weight loss drugs, Mounjaro and Zepbound. Despite its massive $850 billion
market cap and a high price-to-earnings ratio of 110-times, on a forward-looking
basis, this stock does appear to be reasonably priced, given the growth
catalysts at hand. On a forward basis, the company’s price-earnings multiple
comes down to a more manageable 36-times. 



I do think the company’s forward expected revenue growth profile is what makes
the stock worth considering. On a forward price-earnings-to-growth (PEG) basis,
LLY stock trades at a multiple of 0.85. That means its earnings are expected to
grow faster than its multiple, meaning this stock will look much cheaper on a
2026 or 2027 basis.

I also think there’s room to forecast this stock out a couple or three years,
due to the company’s recently-launched discounted Zepbound® single-dose vials.
This launch is expected to expand access for self-pay patients amid high demand.
The new vials offer a 50%+ price cut compared to other GLP-1 obesity drugs,
providing more affordable options for those without insurance or savings cards.

For those bullish on the long-term impacts of the weight loss trends we’re
seeing translate into the company’s earnings, this is a stock that’s worth
considering at current levels for long-term growth. 


REGENERON PHARMACEUTICALS (REGN)

Public Domain / Wikimedia Commons
A Regeneron facility

Regeneron Pharmaceuticals (NASDAQ:REGN) develops and sells treatments for
inflammation, cancer, cardiovascular, and eye diseases. The company’s key drugs
include Praluent for cholesterol, Dupixent for immunology, Libtayo for cancer,
and Eylea for eye conditions. Collaborating with Sanofi and others to advance
monoclonal antibodies, RNA interference, and CRISPR-based gene editing
technologies, this is a stock that’s on the cutting edge of developing some of
the most important potential drugs moving forward. That’s likely one of the
reasons why this stock is up more than 300% over the past year.



Of course, having a strong pipeline is one thing, but seeing strong performance
from existing drugs is equally important. The company’s share price has seen
strong price action following its better-than-expected Q2 earnings, with
Regeneron touting strong eczema and eye treatment sales as key drivers of its
12.3% revenue growth figure. The company’s R&D spending grew 10.5% (less than
its overall revenue growth rate), with key investments made in Regeneron’s
obesity drugs and other antibody treatments. 

With a recently-announced $3 billion share buyback program and a strong buy
consensus rating from analysts, I think this stock has further to run from here.


VERTEX PHARMACEUTICALS (VRTX)

PeopleImages / Getty Images
A number of doctors putting their hands together in a circle

Vertex Pharmaceuticals (NASDAQ:VRTX) is known for its diverse biotech portfolio,
including gene-editing, non-opioid painkillers, and potential treatments for
kidney disease and type 1 diabetes. The company’s cystic fibrosis (CF)
franchise, surpassing the impact of its once-prominent hepatitis C drug Incivek,
could cover 90% of the CF population if its drugs gain global and pediatric
approvals. With strong patents and minimal competition, Vertex is set to
maintain its CF market dominance while exploring other rare disease treatments
to boost revenue.

The company’s recently-reported Q2 2024 revenue of $2.65 billion reflected 6%
year-over-year growth, and highlights the strength of the company’s core
pipeline. While Vertex remains heavily dependent on its cystic fibrosis
treatments, and there’s uncertainty over whether certain drugs in its pipeline
will be approved, this stock is perhaps a higher upside pick than the first two
due to its size.



With a comparatively small market capitalization of $112 billion, and a
five-year stock price gain of 175% (still extremely solid, but nowhere close to
the previous two picks on this list), one could argue that Vertex has the
highest upside potential of the three. I think the company’s strong long-term
growth profile driven by a 15% average annual return since its IPO in 1991
should entice many investors to consider this stock on dips moving forward.


WANT TO RETIRE EARLY? START HERE (SPONSOR)

Want retirement to come a few years earlier than you’d planned? Or are you ready
to retire now, but want an extra set of eyes on your finances?

Now you can speak with up to 3 financial experts in your area for FREE. By
simply clicking here you can begin to match with financial professionals who can
help you build your plan to retire early. And the best part? The first
conversation with them is free.

Click here to match with up to 3 financial pros who would be excited to help you
make financial decisions.




Read more: Investing, big pharma, eli lilly, growth stocks, pharma stocks,
pharma stocks to buy, pharmaceuticals, Regeneron, Vertex Pharmaceuticals, weight
loss drugs

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.




LATEST FROM 24/7



6 DIVIDEND KINGS PASSIVE INVESTORS SHOULD BUY HAND-OVER-FIST NOW


GET PAID WHETHER YOU WORK OR NOT? YOU CAN, IF YOU BUY THESE DIVIDEND STOCKS


BILLIONAIRE LEON COOPERMAN HAS 25% OF HIS $2.4 BILLION PORTFOLIO IN JUST 3...


MICROSOFT (MSFT) PRICE PREDICTION AND FORECAST 2025-2030


Home
About Us
Disclaimer and Terms of Use
Privacy Policy
Contact Us
Advertise
© 2024 24/7 Wall St.

✕
Do not sell or share my personal information.
You have chosen to opt-out of the sale or sharing of your information from this
site and any of its affiliates. To opt back in please click the "Customize my ad
experience" link.

This site collects information through the use of cookies and other tracking
tools. Cookies and these tools do not contain any information that personally
identifies a user, but personal information that would be stored about you may
be linked to the information stored in and obtained from them. This information
would be used and shared for Analytics, Ad Serving, Interest Based Advertising,
among other purposes.

For more information please visit this site's Privacy Policy.
CANCEL
CONTINUE


Information from your device can be used to personalize your ad experience.

Do not sell or share my personal information.
A Raptive Partner Site